Classes of drugs that target the cellular components of inflammation under clinical development for COPD

References

• King PT. Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer. Clin Transl Med. 2015;4(1):68.
   PubMedGoogle Scholar
• David B, Bafadhel M, Koenderman L, et al. Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait. Thorax. 2021;76(2):188–195.
   PubMed Web of Science ®Google Scholar
• Yunna C, Mengru H, Lei W, et al. Macrophage M1/M2 polarization. Eur J Pharmacol. 2020;877:173090.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Sica A, Sozzani S, et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25(12):677–686.
   PubMed Web of Science ®Google Scholar
• Yamasaki K, Eeden SFV. Lung macrophage phenotypes and functional responses: role in the pathogenesis of COPD. Int J Mol Sci. 2018;19(2):582.
   Web of Science ®Google Scholar
• Kapellos TS, Bassler K, Aschenbrenner AC, et al. Dysregulated functions of lung macrophage populations in COPD. J Immunol Res. 2018;2018:2349045.
   PubMed Web of Science ®Google Scholar
• Ogger PP, Byrne AJ. Macrophage metabolic reprogramming during chronic lung disease. Mucosal Immunol. 2021;14(2):282–295.
   PubMed Web of Science ®Google Scholar
• Cowland JB, Borregaard N. Granulopoiesis and granules of human neutrophils. Immunol Rev. 2016;273(1):11–28.
   PubMed Web of Science ®Google Scholar
• Korkmaz B, Caughey GH, Chapple I, et al. Therapeutic targeting of cathepsin C: from pathophysiology to treatment. Pharmacol Ther. 2018;190:202–236.
   PubMed Web of Science ®Google Scholar
• Casanova-Acebes M, Nicolás-Ávila JA, Li JL, et al. Neutrophils instruct homeostatic and pathological states in naive tissues. J Exp Med. 2018;215(11):2778–2795.
   PubMed Web of Science ®Google Scholar
• Tian F, Han Y, Song J, et al. Pulmonary resident neutrophils regulate the production of GM-CSF and alveolar macrophages. FEBS J. 2016;283(8):1465–1474.
   PubMed Web of Science ®Google Scholar
• Tavares LP, Peh HY, Tan WSD, et al. Granulocyte-targeted therapies for airway diseases. Pharmacol Res. 2020;157:104881.
   PubMed Web of Science ®Google Scholar
• Sallusto F, Mackay CR, Lanzavecchia A. The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol. 2000;18(1):593–620.
   PubMedGoogle Scholar
• Rudd JM, Pulavendran S, Ashar HK, et al. Neutrophils induce a novel chemokine receptors repertoire during influenza pneumonia. Front Cell Infect Microbiol. 2019;9:108.
   PubMed Web of Science ®Google Scholar
• Liew PX, Kubes P. The neutrophil’s role during health and disease. Physiol Rev. 2019;99(2):1223–1248.
   PubMed Web of Science ®Google Scholar
• Uddin M, Watz H, Malmgren A, et al. NETopathic inflammation in chronic obstructive pulmonary disease and severe asthma. Front Immunol. 2019;10:47.
   PubMed Web of Science ®Google Scholar
• Brusselle G, Pavord ID, Landis S, et al. Blood eosinophil levels as a biomarker in COPD. Respir Med. 2018;138:21–31.
   PubMed Web of Science ®Google Scholar
• Ts H, Henderson WRJ. An update on the role of leukotrienes in asthma. Curr Opin Allergy Clin Immunol. 2010;10(1):60–66.
   PubMed Web of Science ®Google Scholar
• Doyle AD, Mukherjee M, LeSuer WE, et al. Eosinophil-derived IL-13 promotes emphysema. Eur Respir J. 2019;53(5):1801291.
   PubMed Web of Science ®Google Scholar
• Eltboli O, Brightling CE. Eosinophils as diagnostic tools in chronic lung disease. Expert Rev Respir Med. 2013;7(1):33–42.
   PubMed Web of Science ®Google Scholar
• Qiu Q, Dan X, Yang C, et al. Increased airway T lymphocyte microparticles in chronic obstructive pulmonary disease induces airway epithelial injury. Life Sci. 2020;261:118357.
   PubMed Web of Science ®Google Scholar
• Tetley TD. Inflammatory cells and chronic obstructive pulmonary disease. Curr Drug Targets Inflamm Allergy. 2005;4(6):607–618.
   PubMedGoogle Scholar
• Williams M, Todd I, Fairclough LC. The role of CD8 + T lymphocytes in chronic obstructive pulmonary disease: a systematic review. Inflamm Res. 2021;70(1):11–18.
   PubMed Web of Science ®Google Scholar
• Grumelli S, Corry DB, Song LZ, et al. An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema. PLoS Med. 2004;1(1):e8.
   PubMed Web of Science ®Google Scholar
• Freeman CM, McCubbrey AL, Crudgington S, et al. Basal gene expression by lung CD4+ T cells in chronic obstructive pulmonary disease identifies independent molecular correlates of airflow obstruction and emphysema extent. PLoS One. 2014;9(5):e96421.
   PubMed Web of Science ®Google Scholar
• Sullivan JL, Bagevalu B, Glass C, et al. B cell-adaptive immune profile in emphysema-predominant chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2019;200(11):1434–1439.
   PubMed Web of Science ®Google Scholar
• Gamble E, Qiu Y, Wang D, et al. Variability of bronchial inflammation in chronic obstructive pulmonary disease: implications for study design. Eur Respir J. 2006;27(2):293–299.
   PubMed Web of Science ®Google Scholar
• Higham A, Leow-Dyke S, Jackson N, et al. Stability of eosinophilic inflammation in COPD bronchial biopsies. Eur Respir J. 2020;56(5):2000622.
   PubMed Web of Science ®Google Scholar
• Contoli M, Baraldo S, Conti V, et al. Airway inflammatory profile is correlated with symptoms in stable COPD: a longitudinal proof-of-concept cohort study. Respirology. 2020;25(1):80–88.
   PubMed Web of Science ®Google Scholar
• Higham A, Booth G, Lea S, et al. The effects of corticosteroids on COPD lung macrophages: a pooled analysis. Respir Res. 2015;16(1):98.
   PubMedGoogle Scholar
• Cazzola M, Page CP, Calzetta L, et al. Emerging anti-inflammatory strategies for COPD. Eur Respir J. 2012 Sep;40(3):724–741.
   PubMed Web of Science ®Google Scholar
• Trevethick MA, Mantell SJ, Stuart EF, et al. Treating lung inflammation with agonists of the adenosine A2A receptor: promises, problems and potential solutions. Br J Pharmacol. 2008;155(4):463–474.
   PubMed Web of Science ®Google Scholar
• Owen C. Chemokine receptors in airway disease: which receptors to target? Pulm Pharmacol Ther. 2001;14(3):193–202.
   PubMed Web of Science ®Google Scholar
• Birrell MA, Wong S, McCluskie K, et al. Second-generation inhibitors demonstrate the involvement of p38 mitogen-activated protein kinase in post-transcriptional modulation of inflammatory mediator production in human and rodent airways. J Pharmacol Exp Ther. 2006;316(3):1318–1327.
   PubMed Web of Science ®Google Scholar
• Thomas MJ, Smith A, Head DH, et al. Airway inflammation: chemokine-induced neutrophilia and the class I phosphoinositide 3-kinases. Eur J Immunol. 2005;35(4):1283–1291.
   PubMed Web of Science ®Google Scholar
• Hicks A, Monkarsh SP, Hoffman AF, et al. Leukotriene B4 receptor antagonists as therapeutics for inflammatory disease: preclinical and clinical developments. Expert Opin Investig Drugs. 2007;16(12):1909–1920.
   PubMed Web of Science ®Google Scholar
• Burian B, Storka A, Marzluf BA, et al. Vasoactive intestinal peptide (VIP) receptor expression in monocyte-derived macrophages from COPD patients. Peptides. 2010;31(4):603–608.
   PubMed Web of Science ®Google Scholar
• Boutten A, Goven D, Artaud-Macari E, et al. NRF2 targeting: a promising therapeutic strategy in chronic obstructive pulmonary disease. Trends Mol Med. 2011;17(7):363–371.
   PubMed Web of Science ®Google Scholar
• Akata K, Van Eeden SF. Lung macrophage functional properties in chronic obstructive pulmonary disease. Int J Mol Sci. 2020;21(3):853.
   Web of Science ®Google Scholar
• Hodge S, Hodge G, Holmes M, et al. Increased airway epithelial and T-cell apoptosis in COPD remains despite smoking cessation. Eur Respir J. 2005;25(3):447–454.
   PubMed Web of Science ®Google Scholar
• Nakanishi Y, Kobayashi D, Asano Y, et al. Clarithromycin prevents smoke-induced emphysema in mice. Am J Respir Crit Care Med. 2009;179(4):271–278.
   PubMed Web of Science ®Google Scholar
• Hodge S, Hodge G, Jersmann H, et al. Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;178(2):139–148.
   PubMed Web of Science ®Google Scholar
• Yamaryo T, Oishi K, Yoshimine H, et al. Fourteen-member macrolides promote the phosphatidylserine receptor-dependent phagocytosis of apoptotic neutrophils by alveolar macrophages. Antimicrob Agents Chemother. 2003;47(1):48–53.
   PubMed Web of Science ®Google Scholar
• Taylor AE, Finney-Hayward TK, Quint JK, et al. Defective macrophage phagocytosis of bacteria in COPD. Eur Respir J. 2010;35(5):1039–1047.
   PubMed Web of Science ®Google Scholar
• Hodge S, Reynolds PN. Low-dose azithromycin improves phagocytosis of bacteria by both alveolar and monocyte-derived macrophages in chronic obstructive pulmonary disease subjects. Respirology. 2012;17(5):802–807.
   PubMed Web of Science ®Google Scholar
• Zhang B, Kopper TJ, Liu X, et al. Macrolide derivatives reduce proinflammatory macrophage activation and macrophage-mediated neurotoxicity. CNS Neurosci Ther. 2019;25(5):591–600.
   PubMed Web of Science ®Google Scholar
• Hodge S, Tran HB, Hamon R, et al. Nonantibiotic macrolides restore airway macrophage phagocytic function with potential anti-inflammatory effects in chronic lung diseases. Am J Physiol Lung Cell Mol Physiol. 2017;312(5):L678–87.
   PubMed Web of Science ®Google Scholar
• Tarran R, Sabater JR, Clarke TC, et al. Nonantibiotic macrolides prevent human neutrophil elastase-induced mucus stasis and airway surface liquid volume depletion. Am J Physiol Lung Cell Mol Physiol. 2013;304(11):L746–56.
   PubMed Web of Science ®Google Scholar
• Sadamatsu H, Takahashi K, Tashiro H, et al. The non-antibiotic macrolide EM900 attenuates HDM and poly(I:C)-induced airway inflammation with inhibition of macrophages in a mouse model. Inflamm Res. 2020;69(1):139–151.
   PubMed Web of Science ®Google Scholar
• Sugawara A, Shima H, Sueki A, et al. Non-antibiotic 12-membered macrolides: design, synthesis and biological evaluation in a cigarette-smoking model. J Antibiot (Tokyo). 2016;69(4):319–326.
   PubMed Web of Science ®Google Scholar
• Morimoto K, Janssen WJ, Fessler MB, et al. Lovastatin enhances clearance of apoptotic cells (efferocytosis) with implications for chronic obstructive pulmonary disease. J Immunol. 2006;176(12):7657–7665.
   PubMed Web of Science ®Google Scholar
• Jin Y, Tachibana I, Takeda Y, et al. Statins decrease lung inflammation in mice by upregulating tetraspanin CD9 in macrophages. PLoS One. 2013;8(9):e73706.
   PubMed Web of Science ®Google Scholar
• Bellosta S, Via D, Canavesi M, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol. 1998;18(11):1671–1678.
   PubMed Web of Science ®Google Scholar
• Kim SE, Thanh Thuy TT, Lee JH, et al. Simvastatin inhibits induction of matrix metalloproteinase-9 in rat alveolar macrophages exposed to cigarette smoke extract. Exp Mol Med. 2009;41(4):277–287.
   PubMed Web of Science ®Google Scholar
• Maneechotesuwan K, Wongkajornsilp A, Adcock IM, et al. Simvastatin suppresses airway IL-17 and upregulates IL-10 in patients with stable COPD. Chest. 2015;148(5):1164–1176.
   PubMed Web of Science ®Google Scholar
• Baßler K, Fujii W, Kapellos TS, et al. Alterations of multiple alveolar macrophage states in chronic obstructive pulmonary disease. bioRxiv. 2020. 05.28.121541. 10.1101/2020.05.28.121541.
   Google Scholar
• Ingebrigtsen TS, Marott JL, Nordestgaard BG, et al. Statin use and exacerbations in individuals with chronic obstructive pulmonary disease. Thorax. 2015;70(1):33–40.
   PubMed Web of Science ®Google Scholar
• Barber R, Baillie GS, Bergmann R, et al. Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers. Am J Physiol Lung Cell Mol Physiol. 2004;287(2):L332–43.
   PubMed Web of Science ®Google Scholar
• Shakur Y, Holst LS, Landstrom TR. Met al. Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family. Prog Nucleic Acid Res Mol Biol. 2001;66:241–277.
   PubMed Web of Science ®Google Scholar
• Buenestado A, Grassin-Delyle S, Guitard F, et al. Roflumilast inhibits the release of chemokines and TNF-α from human lung macrophages stimulated with lipopolysaccharide. Br J Pharmacol. 2012;165(6):1877–1890.
   PubMed Web of Science ®Google Scholar
• Lea S, Metryka A, Li J, et al. The modulatory effects of the PDE4 inhibitors CHF6001 and roflumilast in alveolar macrophages and lung tissue from COPD patients. Cytokine. 2019;123:154739.
   PubMed Web of Science ®Google Scholar
• Watz H, Mistry SJ, Lazaar AL. Safety and tolerability of the inhaled phosphodiesterase 4 inhibitor GSK256066 in moderate COPD. Pulm Pharmacol Ther. 2013;26(5):588–595.
   PubMed Web of Science ®Google Scholar
• Franciosi LG, Diamant Z, Banner KH, et al. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. Lancet Respir Med. 2013;1(9):714–727.
   PubMed Web of Science ®Google Scholar
• Kaur M, Beardsall M, Salmon M, et al. GS-5759, A novel bi-functional phosphodiesterase 4 inhibitor and long-acting β2-adrenoceptor agonist inhibits cytokine production from COPD alveolar macrophages [abstract]. Am J Respir Crit Care Med. 2012;185:A5705.
   Google Scholar
• Murugaiah V, Tsolaki AG, Kishore U. Collectins: innate immune pattern recognition molecules. Adv Exp Med Biol. 2020;1204:75–127.
   PubMed Web of Science ®Google Scholar
• Sano H, Chiba H, Iwaki D, et al. Surfactant proteins A and D bind CD14 by different mechanisms. J Biol Chem. 2000;275(29):22442–22451.
   PubMed Web of Science ®Google Scholar
• Watson A, Madsen J, Clark HW. SP-A and SP-D: dual functioning immune molecules with antiviral and immunomodulatory properties. Front Immunol. 2021;11:622598.
   PubMed Web of Science ®Google Scholar
• Winkler C, Atochina-Vasserman EN, Holz O, et al. Comprehensive characterisation of pulmonary and serum surfactant protein D in COPD. Respir Res. 2011;12(1):29.
   PubMedGoogle Scholar
• Hodge S, Matthews G, Dean MM, et al. Therapeutic role for mannose-binding lectin in cigarette smoke-induced lung inflammation? Evidence from a murine model. Am J Respir Cell Mol Biol. 2010;42(2):235–242.
   PubMed Web of Science ®Google Scholar
• Pilecki B, Wulf-Johansson H, Støttrup C, et al. Surfactant protein D deficiency aggravates cigarette smoke-induced lung inflammation by upregulation of ceramide synthesis. Front Immunol. 2018;9:3013.
   PubMed Web of Science ®Google Scholar
• Matera MG, Cazzola M, Page C. Prospects for COPD treatment. Curr Opin Pharmacol. 2021;56:74–84.
   PubMed Web of Science ®Google Scholar
• Jones NA, Boswell-Smith V, Lever R, et al. The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro. Pulm Pharmacol Ther. 2005;18(2):93–101.
   PubMed Web of Science ®Google Scholar
• Rogliani P, Calzetta L, Cazzola M, et al. Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis. Expert Opin Drug Saf. 2016;15(8):1133–1146.
   PubMed Web of Science ®Google Scholar
• Matera MG, Rogliani P, Calzetta L, et al. Phosphodiesterase inhibitors for chronic obstructive pulmonary disease: what does the future hold? Drugs. 2014;74(17):1983–1992.
   PubMed Web of Science ®Google Scholar
• Singh D, Beeh KM, Colgan B, et al. Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD. Respir Res. 2019;20(1):180.
   PubMed Web of Science ®Google Scholar
• Page C, Cazzola M. Bifunctional drugs for the treatment of respiratory diseases. Handb Exp Pharmacol. 2017;237:197–212.
   PubMedGoogle Scholar
• Cazzola M, Calzetta L, Rogliani P, et al. Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD. Expert Opin Investig Drugs. 2019;28(10):827–833.
   PubMed Web of Science ®Google Scholar
• Matera MG, Ora J, Cavalli F, et al. New avenues for phosphodiesterase inhibitors in asthma. J Exp Pharmacol. 2021;13:291–302.
   PubMedGoogle Scholar
• Keir HR, Richardson H, Fillmore C, et al. CXCL-8-dependent and -independent neutrophil activation in COPD: experiences from a pilot study of the CXCR2 antagonist danirixin. ERJ Open Res. 2020;6(4):00583–2020. 10.1183/23120541.00583-2020.
   PubMedGoogle Scholar
• Lazaar AL, Miller BE, Tabberer M, et al. Effect of the CXCR2 antagonist danirixin on symptoms and health status in COPD. Eur Respir J. 2018;52(4):1801020.
   PubMed Web of Science ®Google Scholar
• Lazaar AL, Miller BE, Donald AC, et al. CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial. Respir Res. 2020;21(1):149.
   PubMed Web of Science ®Google Scholar
• Jurcevic S, Humfrey C, Uddin M, et al. The effect of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune functions. Br J Clin Pharmacol. 2015;80(6):1324–1336.
   PubMed Web of Science ®Google Scholar
• Nair P, Gaga M, Zervas E, et al. Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial. Clin Exp Allergy. 2012;42(7):1097–1103.
   PubMed Web of Science ®Google Scholar
• Lo Bello F, Hansbro PM, Donovan C, et al. New drugs under development for COPD. Expert Opin Emerg Drugs. 2020;25(4):419–431.
   PubMed Web of Science ®Google Scholar
• Pelaia C, Vatrella A, Sciacqua A, et al. Role of p38-mitogen-activated protein kinase in COPD: pathobiological implications and therapeutic perspectives. Expert Rev Respir Med. 2020;14(5):485–491.
   PubMed Web of Science ®Google Scholar
• Defnet AE, Hasday JD, Shapiro P. Kinase inhibitors in the treatment of obstructive pulmonary diseases. Curr Opin Pharmacol. 2020;51:11–18.
   PubMed Web of Science ®Google Scholar
• Patel NR, Cunoosamy DM, Fagerås M, et al. The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial. Int J Chron Obstruct Pulmon Dis. 2018;13:1009–1019.
   PubMed Web of Science ®Google Scholar
• Charron CE, Russell P, Ito K, et al. RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-α and -γ selectivity, suppresses COPD inflammation. Eur Respir J. 2017;50(4):1700188.
   PubMed Web of Science ®Google Scholar
• Marwick JA, Caramori G, Stevenson CS, et al. Inhibition of PI3Kdelta restores glucocorticoid function in smoking-induced airway inflammation in mice. Am J Respir Crit Care Med. 2009;179(7):542–548.
   PubMed Web of Science ®Google Scholar
• Gupta V, Khan A, Higham A, et al. The effect of phosphatidylinositol-3 kinase inhibition on matrix metalloproteinase-9 and reactive oxygen species release from chronic obstructive pulmonary disease neutrophils. Int Immunopharmacol. 2016;35:155–162.
   PubMed Web of Science ®Google Scholar
• Cahn A, Hamblin JN, Begg M, et al. Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD. Pulm Pharmacol Ther. 2017;46:69–77.
   PubMed Web of Science ®Google Scholar
• Tvaroška I, Selvaraj C, Koča J. Selectins - The two Dr. Jekyll and Mr. Hyde faces of adhesion molecules - A review. Molecules. 2020;25(12):2835.
   Web of Science ®Google Scholar
• Di Stefano A, Maestrelli P, Roggeri A, et al. Upregulation of adhesion molecules in the bronchial mucosa of subjects with chronic obstructive bronchitis. Am J Respir Crit Care Med. 1994;149(3):803–810.
   PubMed Web of Science ®Google Scholar
• Watz H, Bock D, Meyer M, et al. Inhaled pan-selectin antagonist Bimosiamose attenuates airway inflammation in COPD. Pulm Pharmacol Ther. 2013;26(2):265–270.
   PubMed Web of Science ®Google Scholar
• Wang C, Zhou J, Wang J, et al. Progress in the mechanism and targeted drug therapy for COPD. Signal Transduct Target Ther. 2020;5(1):248.
   PubMed Web of Science ®Google Scholar
• Bedard PW, Kaila N. Selectin inhibitors: a patent review. Expert Opin Ther Pat. 2010;20(6):781–793.
   PubMed Web of Science ®Google Scholar
• Le Rouzic O, Pichavant M, Frealle E, et al. Th17 cytokines: novel potential therapeutic targets for COPD pathogenesis and exacerbations. Eur Respir J. 2017;50(4):1602434.
   PubMed Web of Science ®Google Scholar
• Eich A, Urban V, Jutel M, et al. A randomized, placebo-controlled phase 2 trial of CNTO 6785 in chronic obstructive pulmonary disease. COPD. 2017;14(5):476–483.
   PubMedGoogle Scholar
• Busse WW, Holgate S, Kerwin E, et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med. 2013;188(11):1294–1302.
   PubMed Web of Science ®Google Scholar
• Khokhlovich E, Grant S, Kazani S, et al. The biological pathways underlying response to anti-IL-17A (AIN457; secukinumab) therapy differ across severe asthmatic patients [abstract]. Eur Respir J. 2017;50(suppl61):OA2897.
   Google Scholar
• Kirsten A, Watz H, Pedersen F, et al. The anti-IL-17A antibody secukinumab does not attenuate ozone-induced airway neutrophilia in healthy volunteers. Eur Respir J. 2013;41(1):239–241.
   PubMed Web of Science ®Google Scholar
• Dahl R, Titlestad I, Lindqvist A, et al. Effects of an oral MMP-9 and −12 inhibitor, AZD1236, on biomarkers in moderate/severe COPD: a randomised controlled trial. Pulm Pharmacol Ther. 2012;25(2):169–177.
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, Aquino TO, O’Brien CD, et al. A randomised, placebo-controlled, dose-finding study of AZD9668, an oral inhibitor of neutrophil elastase, in patients with chronic obstructive pulmonary disease treated with tiotropium. COPD. 2012;9(2):111–120.
   PubMedGoogle Scholar
• Kuna P, Jenkins M, O’Brien CD, et al. AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD. Respir Med. 2012;106(4):531–539. 7578.
   PubMed Web of Science ®Google Scholar
• Watz H, Nagelschmitz J, Kirsten A, et al. Safety and efficacy of the human neutrophil elastase inhibitor BAY 85-8501 for the treatment of non-cystic fibrosis bronchiectasis: a randomized controlled trial. Pulm Pharmacol Ther. 2019;56:86–93.
   PubMed Web of Science ®Google Scholar
• Barth P, Bruijnzeel P, Wach A, et al. Single dose escalation studies with inhaled POL6014, a potent novel selective reversible inhibitor of human neutrophil elastase, in healthy volunteers and subjects with cystic fibrosis. J Cyst Fibros. 2020;19(2):299–304.
   PubMed Web of Science ®Google Scholar
• Crocetti L, Quinn MT, Schepetkin IA, et al. A patenting perspective on human neutrophil elastase (HNE) inhibitors (2014-2018) and their therapeutic applications. Expert Opin Ther Pat. 2019;29(7):555–578.
   PubMed Web of Science ®Google Scholar
• Miller BE, Mayer RJ, Goyal N, et al. Epithelial desquamation observed in a phase I study of an oral cathepsin C inhibitor (GSK2793660). Br J Clin Pharmacol. 2017;83(12):2813–2820.
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Haworth CS, Metersky ML, et al., Phase 2 Trial of the DPP-1 inhibitor brensocatib in bronchiectasis. N Engl J Med. 2020;383(22):2127–2137.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Stolz D, Rogliani P, et al. α1-Antitrypsin deficiency and chronic respiratory disorders. Eur Respir Rev. 2020;29(155):190073.
   PubMed Web of Science ®Google Scholar
• Stolk J, Tov N, Chapman KR, et al. Efficacy and safety of inhaled α1-antitrypsin in patients with severe α1-antitrypsin deficiency and frequent exacerbations of COPD. Eur Respir J. 2019;54(5):1900673.
   PubMed Web of Science ®Google Scholar
• Tumpara S, Martinez-Delgado B, Gomez-Mariano G, et al. The delivery of α1-antitrypsin therapy through transepidermal route: worthwhile to explore. Front Pharmacol. 2020;11:983.
   PubMed Web of Science ®Google Scholar
• Trivedi A, Khan MA, Bade G, et al., Orchestration of neutrophil extracellular traps (Nets), a unique innate immune function during chronic obstructive pulmonary disease (COPD) development. Biomedicines. 2021;9(1):53.
   PubMed Web of Science ®Google Scholar
• Fieldes M, Bourguignon C, Assou S, et al. Targeted therapy in eosinophilic chronic obstructive pulmonary disease. ERJ Open Res. 2021;7(2):00437–2020.
   PubMedGoogle Scholar
• Roufosse F. Targeting the interleukin-5 pathway for treatment of eosinophilic conditions other than asthma. Front Med (Lausanne). 2018;5:49.
   PubMed Web of Science ®Google Scholar
• Bafadhel M, Saha S, Siva R, et al. Sputum IL-5 concentration is associated with a sputum eosinophilia and attenuated by corticosteroid therapy in COPD. Respiration. 2009;78(3):256–262.
   PubMed Web of Science ®Google Scholar
• Donovan T, Milan SJ, Wang R, et al. Anti-IL-5 therapies for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2020;12:CD013432.
   PubMed Web of Science ®Google Scholar
• Yousuf A, Ibrahim W, Greening NJ, et al. T2 biologics for chronic obstructive pulmonary disease. J Allergy Clin Immunol Pract. 2019;7(5):1405–1416.
   PubMed Web of Science ®Google Scholar
• Brightling CE, Bleecker ER, Panettieri RA, et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med. 2014;2(11):891–901.
   PubMed Web of Science ®Google Scholar
• Mesnil C, Raulier S, Paulissen G, et al. Lung-resident eosinophils represent a distinct regulatory eosinophil subset. J Clin Invest. 2016;126(9):3279–3295.
   PubMed Web of Science ®Google Scholar
• Matera MG, Rogliani P, Calzetta L, et al. TSLP inhibitors for asthma: current status and future prospects. Drugs. 2020;80(5):449–458.
   PubMed Web of Science ®Google Scholar
• Zhang K, Shan L, Rahman MS, et al. Constitutive and inducible thymic stromal lymphopoietin expression in human airway smooth muscle cells: role in chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol. 2007;293(2):L375–82.
   PubMed Web of Science ®Google Scholar
• Redhu NS, Gounni AS. Function and mechanisms of TSLP/TSLPR complex in asthma and COPD. Clin Exp Allergy. 2012;42(7):994–1005.
   PubMed Web of Science ®Google Scholar
• Gabryelska A, Kuna P, Antczak A, et al. IL-33 mediated inflammation in chronic respiratory diseases - Understanding the role of the member of IL-1 superfamily. Front Immunol. 2019;10:692.
   PubMed Web of Science ®Google Scholar
• Kim WD, Chi HS, Choe KH, et al. The role of granzyme B containing cells in the progression of chronic obstructive pulmonary disease. Tuberc Respir Dis (Seoul). 2020;83(Supple1):S25–S33.
   PubMedGoogle Scholar
• Shen Y, Zeglinski MR, Turner CT, et al. Topical small molecule granzyme B inhibitor improves remodeling in a murine model of impaired burn wound healing. Exp Mol Med. 2018;50(5):1–11.
   Google Scholar
• Aslam MS, Yuan L. Serpina3n: potential drug and challenges, mini review. J Drug Target. 2020;28(4):368–378.
   PubMed Web of Science ®Google Scholar
• Ikram S, Ahmad J, Durdagi S. Screening of FDA approved drugs for finding potential inhibitors against Granzyme B as a potent drug-repurposing target. J Mol Graph Model. 2020;95:107462.
   PubMed Web of Science ®Google Scholar
• Hodge S, Hodge G, Holmes M, et al. Increased CD8 T-cell granzyme B in COPD is suppressed by treatment with low-dose azithromycin. Respirology. 2015;20(1):95–100.
   PubMed Web of Science ®Google Scholar
• Hodge G, Holmes M, Jersmann H, et al. Targeting peripheral blood pro-inflammatory cytotoxic lymphocytes by inhibiting CD137 expression: novel potential treatment for COPD. BMC Pulm Med. 2014;14:85.
   PubMed Web of Science ®Google Scholar
• Hodge G, Hodge S. Steroid Resistant CD8+CD28null NKT-like pro-inflammatory cytotoxic cells in chronic obstructive pulmonary disease. Front Immunol. 2016;7:617.
   PubMed Web of Science ®Google Scholar
• Chu DT, Bac ND, Nguyen KH, et al. An update on anti-CD137 antibodies in immunotherapies for cancer. Int J Mol Sci. 2019;20(8):1822.
   PubMed Web of Science ®Google Scholar
• Segreti A, Stirpe E, Rogliani P, et al. Defining phenotypes in COPD: an aid to personalized healthcare. Mol Diagn Ther. 2014;18(4):381–388.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Rogliani P, et al. The challenges of precision medicine in COPD. Mol Diagn Ther. 2017;21(4):345–355.
   PubMed Web of Science ®Google Scholar
• Wenzel SE. Severe adult asthmas: integrating clinical features, biology, and therapeutics to improve outcomes. Am J Respir Crit Care Med. 2021;203(7):809–821.
   PubMed Web of Science ®Google Scholar
• Rabe KF, Watz H, Baraldo S, et al. Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial. Lancet Respir Med. 2018;6(11):827–836.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. 2021 report. Available at: https://goldcopd.org/. (Accessed 2021 Apr 15).
   Google Scholar
• Mkorombindo T, Dransfield MT. Inhaled corticosteroids in chronic obstructive pulmonary disease: benefits and risks. Clin Chest Med. 2020;41(3):475–484.
   PubMed Web of Science ®Google Scholar
• Janson C, Johansson G, Ställberg B, et al. Identifying the associated risks of pneumonia in COPD patients: ARCTIC an observational study. Respir Res. 2018;19(1):172.
   PubMedGoogle Scholar
• Narendra DK, Hanania NA. Targeting IL-5 in COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:1045–1051.
   PubMed Web of Science ®Google Scholar
• Hughes MJ, Sapey E, Stockley R. Neutrophil phenotypes in chronic lung disease. Expert Rev Respir Med. 2019;13(10):951–967.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Rogliani P, Stolz D, et al. Pharmacological treatment and current controversies in COPD. F1000Res. F1000 Faculty Rev-1533 2019;8:1533.
   PubMedGoogle Scholar
• Calzetta L, Matera MG, Rogliani P, et al. The role of triple therapy in the management of COPD. Expert Rev Clin Pharmacol. 2020;13(8):865–874.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Rogliani P, Puxeddu E, et al. An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations? Expert Rev Respir Med. 2018;12(1):43–54.
   PubMed Web of Science ®Google Scholar
• Bourbeau J, Bafadhel M, Barnes NC, et al. Benefit/risk profile of single-inhaler triple therapy in COPD. Int J Chron Obstruct Pulmon Dis. 2021;16:499–517.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Matera MG. Long-acting muscarinic antagonists and small airways in asthma: which link? Allergy. 2021 Feb 9. Epub ahead of print. 10.1111/all.14766
   PubMed Web of Science ®Google Scholar
• Divo M, Celli BR. Multimorbidity in patients with chronic obstructive pulmonary disease. Clin Chest Med. 2020;41(3):405–419.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG, Rogliani P, et al. Treating systemic effects of COPD. Trends Pharmacol Sci. 2007;28(10):544–550.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Rinaldi B, et al. Management of chronic obstructive pulmonary disease in patients with cardiovascular diseases. Drugs. 2017;77(7):721–732.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Rogliani P, Calzetta L, et al. Targeting mechanisms linking COPD to type 2 diabetes mellitus. Trends Pharmacol Sci. 2017;38(10):940–951.
   PubMed Web of Science ®Google Scholar
• Castellano JM, Copeland-Halperin R, Fuster V. Aiming at strategies for a complex problem of medical nonadherence. Glob Heart. 2013;8(3):263–271.
   PubMedGoogle Scholar
• Castellano JM, Sanz G, Fernandez Ortiz A, et al. A polypill strategy to improve global secondary cardiovascular prevention: from concept to reality. J Am Coll Cardiol. 2014;64(6):613–621.
   PubMed Web of Science ®Google Scholar
• Tanner L, Single AB. Animal models reflecting chronic obstructive pulmonary disease and related respiratory disorders: translating pre-clinical data into clinical relevance. J Innate Immun. 2020;12(3):203–225.
   PubMed Web of Science ®Google Scholar
• Nucera F, Lo Bello F, Shen SS, et al. Role of atypical chemokines and chemokine receptors pathways In the pathogenesis of COPD. Curr Med Chem. 2020 Aug 19; doi: 10.2174/0929867327999200819145327. Online ahead of print.
   PubMed Web of Science ®Google Scholar
• Haddad EB, Birrell M, McCluskie K, et al. Role of p38 MAP kinase in LPS-induced airway inflammation in the rat. Br J Pharmacol. 2001;132(8):1715–1724.
   PubMed Web of Science ®Google Scholar
• Zuo H, Cattani-Cavalieri I, Musheshe N, et al. Phosphodiesterases as therapeutic targets for respiratory diseases. Pharmacol Ther. 2019;197:225–242.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Inflammatory endotypes in COPD. Allergy. 2019;74(7):1249–1256.
   PubMed Web of Science ®Google Scholar